NextFin news, On Thursday, October 2, 2025, the Trump administration announced a delay in the planned 100% tariffs on imported brand-name pharmaceutical drugs. The tariffs, initially set to take effect on Wednesday, October 1, were postponed as the administration reviews proposals from drug manufacturers aimed at lowering prices and increasing U.S.-based production.
President Donald Trump had threatened to impose these tariffs last week, targeting brand-name or patented drugs imported into the United States. However, he exempted drugmakers that are investing in building manufacturing plants within the country. A White House official told Scripps News that "President Trump is wholeheartedly committed to lowering drug prices for Americans and will not hesitate to utilize tariffs to do so.”
Brand-name drugs in the U.S. currently cost three to four times more than in other developed countries. The tariffs were expected to impact both brand-name and generic drugs, the latter often imported from Europe, potentially raising prices if enacted.
In May 2025, President Trump signed an executive order mandating drugmakers to provide “most favored nation” pricing, requiring them to offer Medicaid the lowest prices available globally. By the end of July, the administration sent letters to 17 pharmaceutical manufacturers demanding price reductions by September 29.
Earlier this week, Pfizer announced an agreement with the Trump administration to lower drug prices. Under this deal, Pfizer will apply most-favored-nation pricing to Medicaid and guarantee that newly launched drugs will be priced to match the lowest rates offered in other developed countries.
A study published by the Johns Hopkins Carey Business School earlier this year indicated that while tariffs might encourage some branded drug manufacturers to relocate operations to the U.S., generic drugs would likely continue to be imported due to cost considerations. The study also suggested that tariffs could lead to increased prices for both generic and brand-name drugs.
The White House official emphasized that the administration is still evaluating the effectiveness of the proposals from pharmaceutical companies and that the tariffs remain a tool to be used if necessary to ensure affordable drug prices for Americans.
Explore more exclusive insights at nextfin.ai.
